How Many Months of Wegovy Does It Take to Lose Weight?

Step 1: The first two months, titration, not transformation

Wegovy's licensed dosing schedule starts at 0.25mg once weekly. The dose then increases approximately every four weeks: 0.25mg, 0.5mg, 1.0mg, 1.7mg, and finally 2.4mg. That means most people only reach the full maintenance dose in month four or five. This isn't a flaw in the medicine, it's deliberate design. Slower titration gives your digestive system time to adjust, which significantly reduces the nausea and stomach discomfort that some people experience in the early weeks.

During these first two months, some weight loss does happen. Appetite begins to drop fairly early because semaglutide acts on hunger signals in the brain from the outset. But the losses are typically modest (often in the range of two to four kilograms) and the main work of this phase is tolerability, not dramatic results. A question our prescribers hear most weeks is whether something has gone wrong if the scales barely move in month one. The answer is almost always no: the medicine is doing exactly what it should.

For a closer look at what two months of treatment tends to look like in practice, our two-month Wegovy weight-loss guide covers the detail. The NHS medicines information on semaglutide also explains the dosing schedule in plain language.

Step 2: Months three to six, when the pattern becomes clearer

Once the 2.4mg dose is established, weight loss tends to accelerate. This is the phase that most closely matches the trial curves: consistent, progressive reduction month on month. The STEP 1 trial, published in the New England Journal of Medicine, recorded around 10–12% average body-weight loss by the six-month mark in the semaglutide group, with the full 15% average accumulating over the 68-week study period.

Not everyone follows the same curve. People with a higher starting BMI, those who make meaningful dietary changes alongside treatment, and those who manage GI side effects well tend to lose more quickly in this window. If you are curious about the physical changes people commonly notice during this period, including the effect Wegovy can have on the tongue and appetite-related sensations, our dedicated page covers what to expect. Conversely, plateau periods are common and normal, weight loss is rarely a straight line. If you are concerned that you are not responding, that is exactly the kind of conversation to have with your prescriber rather than adjusting anything yourself.

Six months is also a meaningful clinical checkpoint. NICE's recommendation for semaglutide (Wegovy) suggests reviewing whether treatment is working if less than 5% weight loss has been achieved by that point at the maintenance dose. Our six-month Wegovy weight-loss page goes into what that review typically involves.

Step 3: Months six to twelve and beyond, sustained loss and the longer picture

The full 68-week STEP 1 trial result of approximately 15% average weight reduction only materialises for most participants in the latter half of treatment. Months six through twelve are where the compound effect of appetite reduction, dietary change and increased activity typically delivers the largest total. Some people reach their goals by month nine or ten; others are still losing slowly at month twelve. If you want a realistic sense of where most people stand earlier in treatment, our guide on what to expect from three months on Wegovy sets out the typical picture at that earlier milestone.

The MHRA approved a higher 7.2mg semaglutide dose in early 2026, and trial data at that dose showed an average weight loss of around 20.7% at 72 weeks, narrowing the gap with tirzepatide results significantly. If you are already established on 2.4mg and not achieving the progress you and your prescriber are aiming for, the existence of this higher dose is worth discussing at your next clinical review.

It is also worth understanding that Wegovy is not intended as a short course. Stopping treatment typically leads to weight returning over time, as the underlying biology that drives appetite does not change permanently. NICE's guidance recommends Wegovy for a maximum of two years within a specialist weight management service on the NHS, but the clinical picture for each person is individual. Our Wegovy overview covers the broader context of how treatment is managed, and if you are exploring how Wegovy fits alongside other approaches, the weight-loss treatment overview sets out the full picture. For context on what treatment costs and what is included in a private prescription, our guide to getting Wegovy through a regulated UK pharmacy explains the process clearly.

Wegovy is a prescription-only medicine, and the timeline that is right for you depends on your starting point, your health history, and how you respond. If you'd like to speak to a prescriber about whether Wegovy is appropriate and what a realistic timeline might look like for your situation, you can speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber.